Skip to content
Namilumab
Namilumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against granulocyte-macrophage colony-stimulating factor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Rheumatoid arthritisD001172EFO_0000685M06.9123
PsoriasisD011565EFO_0000676L4011
SarcoidosisD012507EFO_0000690D80-D8911
Pulmonary sarcoidosisD017565DOID_13406D86.011
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients11
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNAMILUMAB
INNnamilumab
Description
Namilumab (human mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL1743044
ChEBI ID
PubChem CID
DrugBank
UNII IDMED485W763 (ChemIDplus, GSRS)
Target
Agency Approved
CSF2
CSF2
Organism
Homo sapiens
Gene name
CSF2
Gene synonyms
GMCSF
NCBI Gene ID
Protein name
granulocyte-macrophage colony-stimulating factor
Protein synonyms
colony stimulating factor 2 (granulocyte-macrophage), Colony-stimulating factor, CSF, granulocyte macrophage-colony stimulating factor, molgramostim, Molgramostin, Sargramostim
Uniprot ID
Mouse ortholog
Csf2 (12981)
granulocyte-macrophage colony-stimulating factor (P01587)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 140 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details